Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).
Status:
Terminated
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and
efficacy of successive intravenous (IV) doses of LFG316 in eligible patients with neovascular
age-related macular degeneration (AMD)